1314 related articles for article (PubMed ID: 25857211)
41. Pathways involved in the resolution of inflammatory joint disease.
Haworth O; Buckley CD
Semin Immunol; 2015 May; 27(3):194-9. PubMed ID: 25944272
[TBL] [Abstract][Full Text] [Related]
42. Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins.
Serhan CN
Curr Opin Clin Nutr Metab Care; 2005 Mar; 8(2):115-21. PubMed ID: 15716788
[TBL] [Abstract][Full Text] [Related]
43. The biosynthetic pathways of the protectins.
Stenvik Haatveit Å; Hansen TV
Prostaglandins Other Lipid Mediat; 2023 Dec; 169():106787. PubMed ID: 37806439
[TBL] [Abstract][Full Text] [Related]
44. Protectins: Their biosynthesis, metabolism and structure-functions.
Vidar Hansen T; Serhan CN
Biochem Pharmacol; 2022 Dec; 206():115330. PubMed ID: 36341938
[TBL] [Abstract][Full Text] [Related]
45. Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome.
Kwon Y
Mol Nutr Food Res; 2020 Feb; 64(4):e1900824. PubMed ID: 31797565
[TBL] [Abstract][Full Text] [Related]
46. Stereoselective syntheses and biological activities of E-series resolvins.
Vik A; Hansen TV
Org Biomol Chem; 2021 Jan; 19(4):705-721. PubMed ID: 33410452
[TBL] [Abstract][Full Text] [Related]
47. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases.
Yacoubian S; Serhan CN
Nat Clin Pract Rheumatol; 2007 Oct; 3(10):570-9; quiz 1 p following 589. PubMed ID: 17906612
[TBL] [Abstract][Full Text] [Related]
48. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation.
Norris PC; Skulas-Ray AC; Riley I; Richter CK; Kris-Etherton PM; Jensen GL; Serhan CN; Maddipati KR
Sci Rep; 2018 Dec; 8(1):18050. PubMed ID: 30575798
[TBL] [Abstract][Full Text] [Related]
49. Proresolution mediators and receptors: novel drug targets for enhancing pharmacological armamentarium against periodontal inflammation.
Grover V; Malhotra R; Kapoor A; Singh J; Sachdeva S
Infect Disord Drug Targets; 2013 Feb; 13(1):75-84. PubMed ID: 23713671
[TBL] [Abstract][Full Text] [Related]
50. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.
Serhan CN
J Periodontol; 2008 Aug; 79(8 Suppl):1520-6. PubMed ID: 18673006
[TBL] [Abstract][Full Text] [Related]
51. Vagus nerve controls resolution and pro-resolving mediators of inflammation.
Mirakaj V; Dalli J; Granja T; Rosenberger P; Serhan CN
J Exp Med; 2014 Jun; 211(6):1037-48. PubMed ID: 24863066
[TBL] [Abstract][Full Text] [Related]
52. Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease.
Spite M
Proc Nutr Soc; 2013 Nov; 72(4):441-50. PubMed ID: 23991833
[TBL] [Abstract][Full Text] [Related]
53. Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis.
Recchiuti A; Mattoscio D; Isopi E
Front Pharmacol; 2019; 10():252. PubMed ID: 31001110
[TBL] [Abstract][Full Text] [Related]
54. Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications.
Wu B; Mottola G; Schaller M; Upchurch GR; Conte MS
Mol Aspects Med; 2017 Dec; 58():72-82. PubMed ID: 28765077
[TBL] [Abstract][Full Text] [Related]
55. The novel lipid mediator PD1
Hansen TV; Dalli J; Serhan CN
Prostaglandins Other Lipid Mediat; 2017 Nov; 133():103-110. PubMed ID: 28602942
[TBL] [Abstract][Full Text] [Related]
56. Novel anti-inflammatory--pro-resolving mediators and their receptors.
Serhan CN; Krishnamoorthy S; Recchiuti A; Chiang N
Curr Top Med Chem; 2011; 11(6):629-47. PubMed ID: 21261595
[TBL] [Abstract][Full Text] [Related]
57. n-3 fatty acid-derived lipid mediators in the brain: new weapons against oxidative stress and inflammation.
Farooqui AA
Curr Med Chem; 2012; 19(4):532-43. PubMed ID: 22204329
[TBL] [Abstract][Full Text] [Related]
58. Resolvins and protectins in the termination program of acute inflammation.
Ariel A; Serhan CN
Trends Immunol; 2007 Apr; 28(4):176-83. PubMed ID: 17337246
[TBL] [Abstract][Full Text] [Related]
59. [What the surgeon needs to know about basic new concepts of inflammation and their therapeutic consequences: sanitation of inflammation is not a passive but rather an active process regulated by lipid mediators].
Gardemann A; Meyer F; Braun-Dullaeus R
Zentralbl Chir; 2013 Jun; 138(3):322-30. PubMed ID: 23807584
[TBL] [Abstract][Full Text] [Related]
60. Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases.
Tang S; Wan M; Huang W; Stanton RC; Xu Y
Mediators Inflamm; 2018; 2018():2380319. PubMed ID: 29674943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
